Pierce K. H. Chow

Pierce K. H. Chow, MBBS, PhD, FRCSEd is a Senior Consultant Surgeon and Professor at the National Cancer Centre Singapore and Duke-NUS Medical School, and is one of Asia's foremost authorities on hepatocellular carcinoma surgery, multidisciplinary management, and clinical trial design. He was the principal investigator of the TACTICS trial—a landmark Japanese/Asia-Pacific phase II study demonstrating that combining TACE with sorafenib significantly improved time-to-untreatable-progression and progression-free survival compared to TACE alone in intermediate-stage HCC—establishing TACE-sorafenib combination as a viable strategy and generating the pivotal concept of "untreatable progression" as a more clinically meaningful endpoint for TACE trials. Dr. Chow has led multiple Asia-Pacific HCC trials investigating hepatic arterial infusion chemotherapy (HAIC), systemic therapy in the perioperative setting, and novel locoregional approaches. He has been instrumental in defining the distinct biological and epidemiological features of HBV-associated HCC in Asian populations and in adapting Western treatment frameworks to the Asia-Pacific context. He is the founding chair of the Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCCG) and has been a driving force in building regional clinical trial infrastructure.